Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan
Alumis to receive $40 million in upfront and near-term co-development payments, with potential for approximately $140 million in additional ...
Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.
NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle ...
pharmaphorum20h
Pharma’s climate change vulnerability and opportunity
As one of the world’s biggest contributors to climate change, pharma is morally obliged to adapt its processes and operations – and doing so will open up new opportunities for growth.